Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chondrochymal
- Development stage
- Phase 2
- Lead developer
- Taiwan Bio Therapeutics
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular
01
Overview
Chondrochymal is an allogeneic bone marrow-derived mesenchymal stem cell (BM-MSC) therapy administered via intra-articular injection for the treatment of knee osteoarthritis. It contains 5.0 x 10^7 BM-MSCs in lactated Ringer's solution and aims to regenerate damaged cartilage tissue in osteoarthritic knees.
- Brand names
- Chondrochymal
- Other names
- Bone marrow mesenchymal stem cellsBM-MSCsBone marrow derived mesenchymal stem cell therapy
Beyond the preview
Go deeper on Chondrochymal.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chondrochymal.